{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:59:06Z","timestamp":1790283546645,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007382","name":"Universidade Federal do Par\u00e1","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007382","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017425","name":"Pr\u00f3-Reitoria de Pesquisa e P\u00f3s-Gradua\u00e7\u00e3o, Universidade Federal do Par\u00e1","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017425","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100028365","name":"Nurse Practitioners of Oregon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100028365","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.clbc.2025.05.022","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T19:16:58Z","timestamp":1749237418000},"page":"625-633","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Adjuvant Chemotherapy in Early Triple-Negative Breast Cancer (T1a-c N0M0): A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0623-8135","authenticated-orcid":false,"given":"Francisco Cezar Aquino de","family":"Moraes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Henrique de Souza","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Beatriz Nardelli","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo Tadeu Freitas Uch\u00f4a","family":"Matheus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina Figueroa","family":"Magalh\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rommel Mario Rodr\u00edguez","family":"Burbano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15 Pt 1","key":"10.1016\/j.clbc.2025.05.022_bib0001","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"31","key":"10.1016\/j.clbc.2025.05.022_bib0002","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.clbc.2025.05.022_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2024.102716","article-title":"Updated cancer burden in oldest old: a population-based study using 2022 Globocan estimates","volume":"95","author":"Shah","year":"2025","journal-title":"Cancer Epidemiol"},{"issue":"2","key":"10.1016\/j.clbc.2025.05.022_bib0004","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3390\/genes15020145","article-title":"Genomic variants and worldwide epidemiology of breast cancer: a genome-wide association studies correlation analysis","volume":"15","author":"da Costa Nunes","year":"2024","journal-title":"Genes"},{"issue":"Suppl 1","key":"10.1016\/j.clbc.2025.05.022_bib0005","first-page":"27","article-title":"Triple negative breast cancers: clinical and prognostic implications","volume":"45","author":"Dawson","year":"2009","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"43","key":"10.1016\/j.clbc.2025.05.022_bib0006","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_390464","article-title":"Early-stage triple-negative breast cancer journey: beginning, end, and everything in between","author":"Han","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.clbc.2025.05.022_bib0007","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2147\/BCTT.S516542","article-title":"Diagnosis, prognosis, and treatment of triple-negative breast cancer: a review","volume":"17","author":"Jie","year":"2025","journal-title":"Breast Cancer Targets Ther"},{"issue":"5","key":"10.1016\/j.clbc.2025.05.022_bib0008","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.3390\/cancers14051253","article-title":"Triple negative breast cancer: updates on classification and treatment in 2021","volume":"14","author":"Bou Zerdan","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.clbc.2025.05.022_bib0009","doi-asserted-by":"crossref","first-page":"vi40","DOI":"10.1093\/annonc\/mds194","article-title":"Adjuvant treatments for triple-negative breast cancers","volume":"23","author":"Joensuu","year":"2012","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.clbc.2025.05.022_bib0010","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1056\/NEJMoa1600249","article-title":"Breast-cancer tumor size, overdiagnosis, and mammography screening effectiveness","volume":"375","author":"Welch","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2025.05.022_bib0011","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.breast.2022.12.004","article-title":"Adjuvant chemotherapy for resected triple negative breast cancer patients: a network meta-analysis","volume":"67","author":"Petrelli","year":"2023","journal-title":"Breast Edinb Scotl"},{"issue":"2","key":"10.1016\/j.clbc.2025.05.022_bib0012","first-page":"187","article-title":"The advance of adjuvant treatment for triple-negative breast cancer","volume":"19","author":"Ge","year":"2021","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.clbc.2025.05.022_bib0013","article-title":"Effects of adjuvant chemotherapy on recurrence rate in T1abN0M0 triple-negative breast cancer: a meta-analysis","volume":"25","author":"Yang","year":"2020","journal-title":"Cancer Treat Res Commun"},{"issue":"10","key":"10.1016\/j.clbc.2025.05.022_bib0014","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clbc.2025.05.022_bib0015","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.clbc.2025.05.022_bib0016","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.clbc.2025.05.022_bib0017","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.clbc.2025.05.022_bib0018","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.clbc.2025.05.022_bib0019","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health"},{"issue":"1","key":"10.1016\/j.clbc.2025.05.022_bib0020","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12874-015-0024-z","article-title":"The heterogeneity statistic I2 can be biased in small meta-analyses","volume":"15","author":"von Hippel","year":"2015","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"10.1016\/j.clbc.2025.05.022_bib0021","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"2","key":"10.1016\/j.clbc.2025.05.022_bib0022","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s10549-023-07132-6","article-title":"Benefit of adjuvant chemotherapy in lymph node-negative, T1b and T1c triple-negative breast cancer","volume":"203","author":"Carbajal-Ochoa","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2025.05.022_bib0023","first-page":"34","article-title":"Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: results of a national multi-institutional retrospective study","volume":"84","author":"de Nonneville","year":"2017","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"1","key":"10.1016\/j.clbc.2025.05.022_bib0024","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10549-021-06481-4","article-title":"Benefit of adjuvant chemotherapy in node-negative T1a versus T1b and T1c triple-negative breast cancer","volume":"192","author":"Fasano","year":"2022","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"10.1016\/j.clbc.2025.05.022_bib0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197523","article-title":"The effect of adjuvant chemotherapy on survival in Korean patients with node negative T1c, triple negative breast cancer","volume":"13","author":"Lim","year":"2018","journal-title":"PloS One"},{"issue":"7","key":"10.1016\/j.clbc.2025.05.022_bib0026","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.clbc.2023.08.002","article-title":"Assessment of use and impact of chemotherapy in lymph node-negative, T1a triple-negative breast cancer","volume":"23","author":"Bravo-Solarte","year":"2023","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2025.05.022_bib0027","first-page":"66","article-title":"Adjuvant chemotherapy in small node-negative triple-negative breast cancer","volume":"135","author":"Steenbruggen","year":"2020","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"1","key":"10.1016\/j.clbc.2025.05.022_bib0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-024-00634-6","article-title":"Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer","volume":"10","author":"Tarantino","year":"2024","journal-title":"Npj Breast Cancer"},{"issue":"20","key":"10.1016\/j.clbc.2025.05.022_bib0029","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1200\/JCO.2013.53.1608","article-title":"Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study","volume":"32","author":"Vaz-Luis","year":"2014","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clbc.2025.05.022_bib0030","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.21037\/gs-22-409","article-title":"Exploration of prognostic factors and the value of adjuvant chemotherapy in T1a,bN0M0 triple-negative breast cancer: a prospective cohort study based on the SEER database","volume":"11","author":"Wu","year":"2022","journal-title":"Gland Surg"},{"issue":"10","key":"10.1016\/j.clbc.2025.05.022_bib0031","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.21037\/gs-23-189","article-title":"Tumor size is associated with adjuvant chemotherapy benefit in T1N0M0 triple-negative breast cancer: a multicenter and propensity score matched analysis","volume":"12","author":"Wu","year":"2023","journal-title":"Gland Surg"},{"issue":"11","key":"10.1016\/j.clbc.2025.05.022_bib0032","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.21881","article-title":"Evaluation of adjuvant treatments for T1 N0 M0 triple-negative breast cancer","volume":"3","author":"Zhai","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clbc.2025.05.022_bib0033","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8880727","article-title":"Survival outcome and impact of chemotherapy in T1 node-negative triple-negative breast cancer: a SEER database analysis","volume":"2020","author":"Zhang","year":"2020","journal-title":"J Oncol"},{"issue":"8","key":"10.1016\/j.clbc.2025.05.022_bib0034","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrc1670","article-title":"Breast cancer metastasis: markers and models","volume":"5","author":"Weigelt","year":"2005","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.1016\/j.clbc.2025.05.022_bib0035","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1200\/JCO.19.00904","article-title":"Phase III trial of Adjuvant Capecitabine after standard Neo-\/adjuvant chemotherapy in patients with early triple-negative breast cancer (GEICAM\/2003-11_CIBOMA\/2004-01)","volume":"38","author":"Lluch","year":"2020","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.clbc.2025.05.022_bib0036","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1200\/JCO.21.00976","article-title":"Randomized phase III postoperative trial of platinum-based chemotherapy versus Capecitabine in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: ECOG-ACRIN EA1131","volume":"39","author":"Mayer","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clbc.2025.05.022_bib0037","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1093\/annonc\/mdt361","article-title":"Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)","volume":"24","author":"Gerber","year":"2013","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"9","key":"10.1016\/j.clbc.2025.05.022_bib0038","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.clbc.2025.05.022_bib0039","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1200\/JCO.21.01536","article-title":"Prognostic value of stromal tumor-infiltrating lymphocytes in young, node-negative, triple-negative breast cancer patients who did not receive (neo)adjuvant systemic therapy","volume":"40","author":"de Jong","year":"2022","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"10","key":"10.1016\/j.clbc.2025.05.022_bib0040","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1001\/jamaoncol.2017.1007","article-title":"Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial","volume":"3","author":"Hahnen","year":"2017","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.clbc.2025.05.022_bib0041","doi-asserted-by":"crossref","first-page":"691","DOI":"10.6004\/jnccn.2022.0030","article-title":"Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Gradishar","year":"2022","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"issue":"10","key":"10.1016\/j.clbc.2025.05.022_bib0042","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdz235","article-title":"Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019","volume":"30","author":"Burstein","year":"2019","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"8","key":"10.1016\/j.clbc.2025.05.022_bib0043","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"10","key":"10.1016\/j.clbc.2025.05.022_bib0044","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.annonc.2021.06.023","article-title":"Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021","volume":"32","author":"Burstein","year":"2021","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"8","key":"10.1016\/j.clbc.2025.05.022_bib0045","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-Gene signature as an aid to treatment decisions in early-stage breast cancer","volume":"375","author":"Cardoso","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clbc.2025.05.022_bib0046","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3816\/CBC.2006.n.051","article-title":"TAILORx: trial assigning individualized options for treatment (Rx)","volume":"7","author":"Sparano","year":"2006","journal-title":"Clin Breast Cancer"},{"issue":"16","key":"10.1016\/j.clbc.2025.05.022_bib0047","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/jnci\/djj305","article-title":"Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer","volume":"98","author":"Hassett","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.clbc.2025.05.022_bib0048","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jama.2020.23370","article-title":"Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment","volume":"325","author":"Wang","year":"2021","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.clbc.2025.05.022_bib0049","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3390\/jpm14050464","article-title":"Cyclin-dependent kinase 4\/6 inhibitors plus endocrine therapy versus endocrine therapy alone for HR-positive, HER-2-negative early breast cancer: meta-analysis of phase III randomized clinical trials","volume":"14","author":"Moraes","year":"2024","journal-title":"J Pers Med"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820925001636?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820925001636?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:56:48Z","timestamp":1762549008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820925001636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1526820925001636"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2025.05.022","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant Chemotherapy in Early Triple-Negative Breast Cancer (T1a-c N0M0): A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2025.05.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}